Publication details
CLOZAPINE AUGMENTATION WITH LONG-ACTING INJECTABLE ANTIPSYCHOTICS - EXPERIENCES IN THE CZECH REPUBLIC
| Authors | |
|---|---|
| Year of publication | 2022 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | Clozapine is the drug of choice for drug-resistant schizophrenia, in which a combination of two antipsychotics with different mechanisms of action had no therapeutic effect. However, many patients have a continuing lack of response to treatment, so clozapine is combined with other psychotropic drugs. In the case of a clozapine-resistant patient who is in addition nonadherent to therapy, augmentation of clozapine with long-acting injectable antipsychotics (LAI APs) is offered. This combination is not yet widely used due to the possible occurrence of side effects (blood dyscrasias, weight gain, hyperglycemia, etc.). Experience with the combination of clozapine and LAI APs suggests that patients who are nonadherent and resistant to clozapine therapy could benefit from this treatment, although the amount of clinical data is currently low. Therefore, augmentation of clozapine with LAI APs should be individualized, based on sufficient medical experience. |